Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY333334 · 1 trial · 1 indication
Number of evaluation points (patches) showing defined Draize score. Erythema and edema were used to determine skin irritation. Score 0 = No Erythema/Edema; Score 1 = Very slight Erythema/Edema (barely perceptible); Score 2 = Well defined Erythema/Edema (edges of area well defined by definite raising); Score 3 = Moderate to Severe Erythema/Edema (raised approximately 1 millimeter \[mm\]).
Number of evaluation points (patches) showing defined Draize score. Erythema and edema were used to determine skin irritation and sensitization. Score 0 = No Erythema/Edema; Score 1 = Very slight Erythema/Edema (barely perceptible); Score 2 = Well defined Erythema/Edema (edges of area well defined by definite raising); Score 3 = Moderate to Severe Erythema/Edema (raised approximately 1 mm); Score 4 = Severe Edema (raised more than 1 mm and extending beyond area of exposure).
| Arm | Type | Description |
|---|---|---|
| LY333334 + placebo | EXPERIMENTAL | Part A: Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, for 22 days Part B: Induction phase: Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, 4 times a week for 3 weeks Rest phase: 2 weeks with no patch application Challenge phase: 80 microgram active patch given once for at least 6 hours |
| Name | Type | Description |
|---|---|---|
| LY333334 | DRUG | Transdermal patch |
| Placebo | DRUG | Transdermal patch |
Inclusion Criteria: * Are overtly healthy postmenopausal females, as determined by medical history, physical examination, vital signs, electrocardiogram (ECG), and laboratory tests (for example, subjects who have osteoporosis or stable and/or controlled hyperlipidemia, hypertension, and/or hypothyr...
LY333334 is an investigational small molecule being studied for postmenopausal osteoporosis. It is in Phase 1 clinical development and has not been approved by the FDA. The drug is being evaluated for its effects in healthy postmenopausal women, with one completed clinical trial assessing skin irritation and sensitization.
LY333334 is a small molecule being developed for postmenopausal osteoporosis. Its specific molecular target has not been disclosed in available information. The drug is in Phase 1 clinical trials, and its mechanism of action is not publicly detailed.
LY333334 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The drug is in Phase 1 clinical development for postmenopausal osteoporosis, with one completed trial involving 251 participants.
LY333334 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, which evaluated the drug's skin irritation and sensitization profile in healthy postmenopausal women.
LY333334 has one completed clinical trial, NCT01250145, titled "A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women." The trial enrolled 251 healthy postmenopausal women in the United States, Germany, and the United Kingdom.
LY333334 is being studied as teriparatide in clinical trials. The completed trial NCT01250145 evaluated teriparatide administered transdermally in healthy postmenopausal women. The drug is in Phase 1 development for postmenopausal osteoporosis, and no alternative names have been disclosed beyond this context.